Building on the 2021 Interim guidance, this second version and update, incorporates the lessons and feedback from the hepatitis pilots that successfully demonstrated the feasibility of measuring hepatitis B and C impact targets to demonstrate elimination, whilst highlighting challenges caused by high disease burden in some countries, as well as delays in reaching mortality targets due to the long natural history of disease progression to liver cirrhosis and hepatocellular carcinoma.
Prevention, diagnosis and treatment of blood borne viruses in Wales: Hepatitis B, hepatitis C and HIV - Annual report 2023
Download
This report provides information on the epidemiology, prevention and control of hepatitis B, hepatitis C and HIV in Wales to end of 2022. The report is aimed at policy makers, health service clinicians and planners, commissioners, criminal justice, third sector agencies and academia.
